about
BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy modelsHuman cell-based artificial antigen-presenting cells for cancer immunotherapy.Specific roles of each TCR hemichain in generating functional chain-centric TCR.Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell ReceptorsCDR3β sequence motifs regulate autoreactivity of human invariant NKT cell receptors.CD4(+) and CD8(+) TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells.Generating De Novo Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain.Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway.Transient stimulation expands superior antitumor T cells for adoptive therapy.Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.A Subset of Human Autoreactive CD1c-Restricted T Cells Preferentially Expresses TRBV4-1+ TCRs.A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.Key Residues at Third CDR3β Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs.Correction: Key Residues at Third CDR3β Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs.Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP84Gly.Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective.DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cellsCapTCR-seq: hybrid capture for T-cell receptor repertoire profilingAn interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trialsA Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II ConsortiumTP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analysesPhase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicitiesImpact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patientsDose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221Chaperones of the class I peptide-loading complex facilitate the constitutive presentation of endogenous antigens on HLA-DP84GGPM87GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironmentPhase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86)Genetic ablation of HLA class I, class II, and the T cell receptor enables allogeneic T cells to be used for adoptive T cell therapy
P50
Q28828457-D75DE270-1751-4D08-81B0-B505AD4AAA8EQ34391263-18F394A2-E4F3-488B-A93D-6E83EDBE18D3Q35205495-F1A95DB9-E20C-4E44-A503-7541FED7B332Q36026142-C8F30D4C-09A7-45C7-82AD-4F099BCB9CEAQ36689593-E964E924-ED9A-44B5-866A-23D63B555EF7Q36748257-A37191B3-9447-479F-AA55-C5808D76AF37Q40496689-06B012E6-4A32-422F-8731-20FD687AC0D3Q41257879-B60E300D-09E5-48D9-816A-BDF434719868Q41988716-B3A1B858-D96C-4CDC-B621-478DF883DC22Q42328616-470198A3-A00D-4B59-9F79-58CFB188F527Q46131627-D42467C2-AADB-4CF9-BD0E-26AA2B35C17EQ47296458-3D00B302-5387-4C32-8002-3C050FDCCB8DQ48106124-8D7EE448-FDB6-41AF-BF78-2EEF1D52EF4CQ48127662-CD71F829-E38C-4514-9845-78DB698BBBE5Q48613436-493A09D2-D9A6-4040-B3A7-D89DC33A4227Q48877738-0CE64471-4FA1-44AE-B45C-21476A362F1EQ52349756-E9C4B868-D9A1-4E01-91CF-CA33002954B5Q55260812-A0C880CF-CFED-4FFF-8F99-DD80954E2BC0Q55322590-887AAFCD-A015-4D10-956D-D0A5CEFAE1DFQ57476121-5A33F090-DD1B-4BD3-BAA3-E0CF642DA567Q59789478-BE552313-6AE4-43F6-96E2-9ED675A5A941Q64098738-7648BC79-65E6-4782-BE67-29D7A4774EBBQ90315378-FED138DA-F18F-469A-8182-588A1D1562D1Q90360577-FE434115-9CC9-4BE3-91FB-3D3EA3DE6E26Q90946277-204982A5-5C69-40FB-B1A1-7A89AAD0082BQ91116654-1E2B648F-60BD-45BB-ABAB-956CAFA71AF5Q91476359-FAC646F4-A1F2-4693-A172-2D1CB08C3D3AQ91621429-C000B05B-3394-43DD-9C2F-C4212474DD1AQ91811860-881948F0-1212-4167-9FFE-F888D0781334Q91899888-844AA56A-42FD-4DC0-9DD7-F7E33667F5C1Q91946723-FFA0ADCE-11BA-442A-97C3-351127D70691Q91972406-214BBCCA-B88C-47EC-AE7C-E51F6E197512Q93011379-E69096D9-9EFA-44ED-86AC-147854E8EC25Q93161784-993E8380-ED81-4B8F-A477-A5E7640406F7
P50
description
researcher, ORCID id # 0000-0002-9840-7057
@en
wetenschapper
@nl
name
Marcus O Butler
@ast
Marcus O Butler
@en
Marcus O Butler
@nl
type
label
Marcus O Butler
@ast
Marcus O Butler
@en
Marcus O Butler
@nl
prefLabel
Marcus O Butler
@ast
Marcus O Butler
@en
Marcus O Butler
@nl
P106
P31
P496
0000-0002-9840-7057